These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31228036)

  • 1. Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis.
    Connell NT; Connors JM
    J Thromb Thrombolysis; 2019 Oct; 48(3):382-386. PubMed ID: 31228036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.
    Li A; Manohar PM; Garcia DA; Lyman GH; Steuten LM
    Thromb Res; 2019 Aug; 180():37-42. PubMed ID: 31200341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF; Meyer G; Segers A; Shi M; Wang TF; Yeo E; Zhang G; Zwicker JI; Weitz JI; Büller HR;
    N Engl J Med; 2018 Feb; 378(7):615-624. PubMed ID: 29231094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
    Nguyen E; Egri F; Mearns ES; White CM; Coleman CI
    Pharmacotherapy; 2016 May; 36(5):488-95. PubMed ID: 27015873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
    Preblick R; Kwong WJ; White RH; Goldhaber SZ
    Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Direct oral anticoagulants in the treatment of cancer-associated thrombosis].
    Stebler-Fontaine L; Rossel A; Marti C; Righini M; Robert-Ebadi H
    Rev Med Suisse; 2019 Dec; 15(674):2232-2235. PubMed ID: 31804034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil.
    Lopes DG; Tamayo A; Schipp B; Siepmann T
    Thromb Res; 2020 Dec; 196():4-10. PubMed ID: 32810773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation.
    Lip GY; Lanitis T; Kongnakorn T; Phatak H; Chalkiadaki C; Liu X; Kuznik A; Lawrence J; Dorian P
    Clin Ther; 2015 Nov; 37(11):2476-2488.e27. PubMed ID: 26477648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.
    Heerey A; Suri S
    Pharmacoeconomics; 2005; 23(9):927-44. PubMed ID: 16153135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.
    Dranitsaris G; Vincent M; Crowther M
    Pharmacoeconomics; 2006; 24(6):593-607. PubMed ID: 16761906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
    Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
    Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
    Avritscher EB; Cantor SB; Shih YC; Escalante CP; Rivera E; Elting LS
    Support Care Cancer; 2004 Jul; 12(7):531-6. PubMed ID: 14986076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.
    Lindmarker P; Holmström M
    J Intern Med; 1996 Dec; 240(6):395-401. PubMed ID: 9010387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
    Abdel-Razeq H; Finianos A; Taher AT
    Expert Rev Hematol; 2018 Jun; 11(6):487-494. PubMed ID: 29791257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis.
    Connell NT; Abel GA; Connors JM
    Thromb Res; 2017 Feb; 150():53-58. PubMed ID: 28039844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
    Shah A; Shewale A; Hayes CJ; Martin BC
    Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.